University of São Paulo Scholl of Medicine, Department of Gastroenterology, Surgical Gastroenterology Discipline (LIM 35), Sao Paulo, Brazil.
Clin Nutr. 2013 Feb;32(1):27-33. doi: 10.1016/j.clnu.2012.08.010. Epub 2012 Aug 23.
BACKGROUND & AIMS: Synbiotic intake may selectively change microbiota composition, restore microbial balance in the gut and improve gastrointestinal functions. We have assessed the clinical response of chronically constipated women to a commercially available synbiotic, combining fructooligosaccharides with Lactobacillus and Bifidobacterium strains (LACTOFOS®).
Following 1 week of non-interventional clinical observation, 100 constipated adult women, diagnosed by ROME III criteria, were randomized to receive two daily doses (6 g) of synbiotic or maltodextrin (placebo group), for 30 days. Treatment response was evaluated by patient's daily record of evacuation (stool frequency, consistency and shape, according to Bristol scale), abdominal symptoms (abdominal pain, bloating and flatulence) and constipation intensity (Constipation Scoring System AGACHAN).
Patients treated with synbiotic had increased frequency of evacuation, as well as stool consistency and shape nearer normal parameters than the placebo group, with significant benefits starting during the second and third weeks, respectively (interaction group/time, P<0.0001). There were no significant differences in abdominal symptoms, but AGACHAN score was better in the synbiotic than in the placebo group.
Dietary supplementation with a synbiotic composed of fructooligosaccharides with Lactobacillus and Bifidobacterium improved evacuation parameters and constipation intensity of chronically constipated women, without influencing abdominal symptoms.
益生菌摄入可能会选择性地改变微生物群落组成,恢复肠道微生物平衡,改善胃肠道功能。我们评估了一种市售益生菌(包含低聚果糖、乳杆菌和双歧杆菌)对慢性便秘女性的临床疗效。
100 例符合罗马 III 标准的成年慢性便秘女性,经过 1 周的非干预性临床观察后,随机分为两组,分别接受每日 2 次(每次 6 克)益生菌或麦芽糊精(安慰剂组)治疗,疗程为 30 天。通过患者每日排便记录(粪便频率、稠度和形状,依据布里斯托大便分类法)、腹部症状(腹痛、腹胀和胃肠气胀)和便秘严重程度(便秘评分系统 AGACHAN)评估治疗反应。
与安慰剂组相比,服用益生菌的患者排便频率增加,粪便稠度和形状更接近正常参数,这种改善分别在第二周和第三周开始显现(组间/时间交互作用,P<0.0001)。两组腹部症状无显著差异,但益生菌组的 AGACHAN 评分优于安慰剂组。
富含低聚果糖的益生菌补充剂可改善慢性便秘女性的排便参数和便秘严重程度,而对腹部症状无影响。